The JenaValve ALIGN-AR Pivotal Trial

NCT ID: NCT04415047

Last Updated: 2022-09-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-22

Study Completion Date

2028-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To collect information about treatment for symptomatic severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aortic regurgitation may include fatigue and shortness of breath. The preferred treatment for severe aortic regurgitation is aortic valve replacement surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will examine the use of TAVR (Transcatheter Aortic Valve Replacement), which is a minimally invasive procedure designed to replace the aortic valve inside the heart. In this study, TAVR will be performed using the JenaValve Pericardial TAVR System, which is intended to help treat symptomatic severe aortic regurgitation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Regurgitation Aortic Valve Insufficiency Aortic Insufficiency Aortic Valve Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transcatheter Aortic Valve Replacement (TAVR)

TAVR with JenaValve Trilogy Heart Valve System Intervention Device: JenaValve Trilogy Heart Valve System

Group Type EXPERIMENTAL

JenaValve Trilogy Heart Valve System

Intervention Type DEVICE

TAVR with JenaValve Trilogy Heart Valve System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JenaValve Trilogy Heart Valve System

TAVR with JenaValve Trilogy Heart Valve System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with severe aortic regurgitation (AR).
* Patient at high risk for open surgical valve replacement
* Patient symptomatic according to NYHA functional class II or higher
* The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB)/ Ethics Committee (EC) of the respective clinical site.

Exclusion Criteria

* Congenital uni or bicuspid aortic valve morphology
* Previous prosthetic aortic valve (bioprosthesis or mechanical) implant
* Endocarditis or other active infection
* Need for urgent or emergent TAVR procedure for any reason
* Cardiogenic shock or hemodynamic instability requiring inotropic support or ventricular assist device
* Severe mitral regurgitation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

JenaValve Technology, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martin B. Leon, MD

Role: STUDY_CHAIR

New York-Presbyterian/ Columbia University Medical Center

Torsten P. Vahl, MD

Role: PRINCIPAL_INVESTIGATOR

New York-Presbyterian/ Columbia University Medical Center

Vinod H. Thourani, MD

Role: PRINCIPAL_INVESTIGATOR

Piedmont Healthcare

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

TMC HealthCare & PIMA Heart

Tucson, Arizona, United States

Site Status

Cedars Sinai Medical Center

Los Angeles, California, United States

Site Status

Scripps Hospital

San Diego, California, United States

Site Status

California Pacific Medical Center Research Institute

San Francisco, California, United States

Site Status

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Morton Plant/ BayCare Health

Clearwater, Florida, United States

Site Status

Piedmont Healthcare

Atlanta, Georgia, United States

Site Status

Emory University Hospital

Atlanta, Georgia, United States

Site Status

Cardiac Surgery Clinical Research Center Inc./ Advocate Aurora Health

Oak Lawn, Illinois, United States

Site Status

University of Maryland Medical Center

Baltimore, Maryland, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Henry Ford Health System

Detroit, Michigan, United States

Site Status

Minneapolis Heart Institute/ Abbott Northwestern

Minneapolis, Minnesota, United States

Site Status

Barnes-Jewish Hospital / Washington University

St Louis, Missouri, United States

Site Status

Rutgers Robert Wood Johnson Medical School/ Rutgers Robert Wood University Hospital

Piscataway, New Jersey, United States

Site Status

New York-Presbyterian/ Columbia University Medical Center

New York, New York, United States

Site Status

The Christ Hospital

Cincinnati, Ohio, United States

Site Status

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

Ohio Health Research Institute

Columbus, Ohio, United States

Site Status

Oregon Health & Science University

Portland, Oregon, United States

Site Status

Allegheny-Singer Health Network

Pittsburgh, Pennsylvania, United States

Site Status

Lankenau

Wynnewood, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Methodist Le Bonheur Healthcare

Memphis, Tennessee, United States

Site Status

Baylor Scott & White Research Institute

Dallas, Texas, United States

Site Status

Houston Methodist

Houston, Texas, United States

Site Status

Memorial Hermann - Texas Medical Center

Houston, Texas, United States

Site Status

Intermountain Medical Center Heart Institute

Salt Lake City, Utah, United States

Site Status

Sentara Hospitals

Norfolk, Virginia, United States

Site Status

University of Washington

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, Hahn RT, Han Y, Hung J, Lang RM, Little SH, Shah DJ, Shernan S, Thavendiranathan P, Thomas JD, Weissman NJ. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017 Apr;30(4):303-371. doi: 10.1016/j.echo.2017.01.007. Epub 2017 Mar 14. No abstract available.

Reference Type BACKGROUND
PMID: 28314623 (View on PubMed)

Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017 Jun 20;135(25):e1159-e1195. doi: 10.1161/CIR.0000000000000503. Epub 2017 Mar 15. No abstract available.

Reference Type BACKGROUND
PMID: 28298458 (View on PubMed)

Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003 Jul;24(13):1231-43. doi: 10.1016/s0195-668x(03)00201-x.

Reference Type BACKGROUND
PMID: 12831818 (View on PubMed)

Geyer M, Tamm AR, Munzel T, Treede H, von Bardeleben RS. Novel Transfemoral TAVR System to Treat Aortic Regurgitation in Degenerated Surgical Aortic Valve Replacement Even in Unfavorable Anatomy. JACC Cardiovasc Interv. 2022 Jun 13;15(11):e135-e136. doi: 10.1016/j.jcin.2022.02.043. Epub 2022 May 11. No abstract available.

Reference Type BACKGROUND
PMID: 35568645 (View on PubMed)

Poschner T, Werner P, Kocher A, Laufer G, Musumeci F, Andreas M, Russo M. The JenaValve pericardial transcatheter aortic valve replacement system to treat aortic valve disease. Future Cardiol. 2022 Feb;18(2):101-113. doi: 10.2217/fca-2021-0065. Epub 2021 Oct 14.

Reference Type BACKGROUND
PMID: 34647465 (View on PubMed)

Ng VG, Khalique OK, Nazif T, Patel A, Hamid N, George I, Bapat V, Hahn R, Kodali S, Vahl TP. Treatment of Acute Aortic Insufficiency With a Dedicated Device. JACC Case Rep. 2021 Mar 24;3(4):645-649. doi: 10.1016/j.jaccas.2021.01.021. eCollection 2021 Apr.

Reference Type BACKGROUND
PMID: 34317595 (View on PubMed)

Vahl TP, Thourani VH, Makkar RR, Hamid N, Khalique OK, Daniels D, McCabe JM, Satler L, Russo M, Cheng W, George I, Aldea G, Sheridan B, Kereiakes D, Golwala H, Zahr F, Chetcuti S, Yadav P, Kodali SK, Treede H, Baldus S, Amoroso N, Ranard LS, Pinto DS, Leon MB. Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study. Lancet. 2024 Apr 13;403(10435):1451-1459. doi: 10.1016/S0140-6736(23)02806-4. Epub 2024 Mar 26.

Reference Type DERIVED
PMID: 38552656 (View on PubMed)

Hamid N, Ranard LS, Khalique OK, Hahn RT, Nazif TM, George I, Ng V, Leon MB, Kodali SK, Vahl TP. Commissural Alignment After Transfemoral Transcatheter Aortic Valve Replacement With the JenaValve Trilogy System. JACC Cardiovasc Interv. 2021 Sep 27;14(18):2079-2081. doi: 10.1016/j.jcin.2021.07.025. No abstract available.

Reference Type DERIVED
PMID: 34556282 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P02C320

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

J-Valve TF Early Feasibility Study
NCT06034028 ACTIVE_NOT_RECRUITING NA
Clinical Trial in China
NCT05580952 UNKNOWN NA
J-Valve Transfemoral Pivotal Study
NCT06455787 RECRUITING NA
Portico Next Generation Approval Study
NCT04011722 ACTIVE_NOT_RECRUITING NA